Efficacy, safety and acceptability of the new pen needle 34G × 3.5 mm: a crossover randomized non-inferiority trial; AGO 02 study

References

• Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Pharmacologic approaches to glycemic treatment. Sec. 8. In Standards of Medical Care in Diabetes – 2017. Diabetes Care 2017;40(Suppl):S64-S74
   Google Scholar
• Hanas R, Ludvigsson J. Experience of pain from insulin injections and needle-phobia in young patients with IDDM. Pract Diabetes Int 1997;14:95-9
   Google Scholar
• Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46:239-46
   PubMed Web of Science ®Google Scholar
• Cemeroglu AP, Can A, Davis AT, et al. Fear of needles in children with type 1 diabetes mellitus on multiple daily injections and continuous subcutaneous insulin infusion. Endocr Pract 2015;21:46-53
   PubMed Web of Science ®Google Scholar
• Benroubi M. Fear, guilt feelings and misconceptions: barriers to effective insulin treatment in type 2 diabetes. Diabetes Res Clin Pract 2011;93(Suppl 1):S97-S9
   PubMed Web of Science ®Google Scholar
• Morris JE, Povey RC, Street CG. Experiences of people with type 2 diabetes who have changed from oral medication to self-administered insulin injections. Pract Diabetes Int 2005;22:239-43
   Google Scholar
• Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-48
   PubMed Web of Science ®Google Scholar
• Korytkowski M, Niskanen L, Asakura T, et al. Addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005;27(Suppl B):S89-S100
   Google Scholar
• Magwire ML. Addressing barriers to insulin therapy: the role of insulin pens. Am J Ther 2011;18:392-402
   PubMed Web of Science ®Google Scholar
• Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther 1998;20:486-96
   PubMed Web of Science ®Google Scholar
• Grabner M, Chu J, Raparla S, et al. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial. Postgrad Med 2013;125:204-13
   PubMed Web of Science ®Google Scholar
• O’Neal KS, Johnson J, Swar S. Nontraditional considerations with insulin needle length selection. Diabetes Spectr 2015;28:264-7
   PubMedGoogle Scholar
• Hirsch LJ, Gibney MA, Albanese J, et al. Comparative glycemic control, safety and patient ratings for a new 4 mm × 32G insulin pen needle in adults with diabetes. Curr Med Res Opin 2010;26:1531-41
   PubMed Web of Science ®Google Scholar
• Hom FG, Ettinger B, Lin MJ. Comparison of serum fructosamine vs glycohemoglobin as measures of glycemic control in a large diabetic population. Acta Diabetol 1998;35:48-51
   PubMed Web of Science ®Google Scholar
• Hom F. Fructosamine, hemoglobin A1c, and measures of diabetic control. Diab Tech Ther 1999;1:443-1445
   PubMedGoogle Scholar
• Smaldone A. Glycemic control and hemoglobinopathy: when A1c may not be reliable. Diab Spectrum 2008;21:46-9
   Google Scholar
• Ross SA, Jamal R, Leiter LA, et al. Evaluation of 8mm insulin pen needles in people with type 1 and type 2 diabetes. Pract Diab Intl 1999;16:145-8
   Google Scholar
• Valentini M, Scardapane M, Bondanini F, et al. Efficacy, safety and acceptability of the new pen needle 33G × 4 mm. AGO 01 study. Curr Med Res Opin 2015;31:487-92
   PubMed Web of Science ®Google Scholar
• Schwartz S, Hassman D, Shelmet J, et al. A multicenter, openlabel, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge ×6mm needle versus a 29 gauge ×12.7mm needle in obese patients with diabetes mellitus. Clin Ther 2004;26:1663-78
   PubMed Web of Science ®Google Scholar
• Kreugel G, Keers JC, Kerstens MN, et al. Randomized trial on the influence of the length of two insulin pen needles on glycemic control and patient preference in obese patients with diabetes. Diabetes Technol Ther 2011;13:737-41
   PubMed Web of Science ®Google Scholar
• McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients’ perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diab Tech Ther 2009;11:195-201
   PubMed Web of Science ®Google Scholar
• Praestmark KA, Stallknecht B, Jensen ML, et al. Injection technique and pen needle design affect leakage from skin after subcutaneous injections. J Diabetes Sci Technol 2016;10:914-22
   PubMedGoogle Scholar
• Powell CV, Kelly AM, Williams A. Determining the minimum clinically significant difference in visual analog pain score for children. Ann Emerg Med 2001;37:28-31
   PubMed Web of Science ®Google Scholar
• Bijur PE, Silver W, Gallagher EJ. Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med 2001;8:1153-7
   PubMed Web of Science ®Google Scholar
• Hanas R, Lytzen L, Ludvigsson J. Thinner needles do not influence injection pain, insulin leakage or bleeding in children and adolescents with type 1 diabetes. Pediatr Diabetes 2000;1:142-9
   PubMedGoogle Scholar
• Birkebaek NH, Solvig J, Hansen B, et al. A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults. Diabetes Care 2008;31:e65
   PubMedGoogle Scholar
• Hofman PL, Derraik JG, Pinto TE, et al. Defining the ideal injection techniques when using 5-mm needles in children and adults. Diabetes Care 2010;33:1940-4
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Strock ES, Peremislov D, et al. Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes. Mayo Clin Proc 2015;90:329-38
   PubMed Web of Science ®Google Scholar
• Wittmann A, Köver J, Kralj N, et al. Insulin leakage value in relation to pen needle length and administered dose after subcutaneous injection. Diabetes Technol Ther 2010;12:587-90
   PubMed Web of Science ®Google Scholar
• Jamal R, Ross SA, Parkes JL, et al. Role of injection technique in use of insulin pens: prospective evaluation of a 31-gauge, 8-mm insulin pen needle. Endocr Pract 1999;5:245-50
   PubMedGoogle Scholar
• Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. Mayo Clin Proc 2016;91:1231-55
   PubMed Web of Science ®Google Scholar